| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1027981860 |
| P356 | DOI | 10.1186/1471-2407-9-112 |
| P932 | PMC publication ID | 2678147 |
| P698 | PubMed publication ID | 19366444 |
| P5875 | ResearchGate publication ID | 24277595 |
| P50 | author | Marc Peeters | Q38324454 |
| P2093 | author name string | Johannes Nippgen | |
| Philippe Rougier | |||
| Jean-Luc Raoul | |||
| Jean-Luc Van Laethem | |||
| Catherine Brezault | |||
| Laurent Cals | |||
| Fares Husseini | |||
| Anja-Helena Loos | |||
| P2860 | cites work | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study | Q33364579 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. | Q34398347 | ||
| The EGFR as a target for anticancer therapy--focus on cetuximab | Q34399317 | ||
| OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. | Q34455189 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Estimates of the cancer incidence and mortality in Europe in 2006. | Q34575047 | ||
| Towards a pan-European consensus on the treatment of patients with colorectal liver metastases | Q36563821 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Q36628049 | ||
| Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. | Q44542780 | ||
| Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. | Q45242224 | ||
| Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. | Q46531455 | ||
| Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. | Q46623103 | ||
| Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma | Q46816802 | ||
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer | Q46892017 | ||
| Induction chemotherapy and surgery of colorectal liver metastases | Q46949107 | ||
| Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. | Q52548591 | ||
| The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. | Q54242652 | ||
| Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors | Q77355550 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note | Q81639244 | ||
| Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates | Q81712809 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| colorectal cancer | Q188874 | ||
| cetuximab | Q420296 | ||
| multicenter clinical trial | Q6934595 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 112 | |
| P577 | publication date | 2009-04-14 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study | |
| P478 | volume | 9 |
| Q26775711 | A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer |
| Q90609968 | A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment |
| Q37856053 | Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab |
| Q37821843 | Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies |
| Q33895581 | Biological agents in gastrointestinal cancers: adverse effects and their management |
| Q39925893 | Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. |
| Q26827240 | Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? |
| Q38051281 | Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. |
| Q37907117 | Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer |
| Q92706903 | Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis |
| Q55260753 | DeCoST: A New Approach in Drug Repurposing From Control System Theory. |
| Q37561771 | EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new? |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q33983663 | Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer |
| Q34663697 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial |
| Q46972709 | First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer |
| Q38183447 | Impact of cetuximab in current treatment of metastatic colorectal cancer. |
| Q43241630 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer |
| Q38086095 | Management of advanced colorectal cancer, Part 2. |
| Q34621577 | New trends in epidermal growth factor receptor-directed monoclonal antibodies |
| Q34488787 | Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342 |
| Q37780016 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. |
| Q33621891 | Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients |
| Q37708010 | Role of cetuximab in first-line treatment of metastatic colorectal cancer |
| Q34541316 | Synchronous oesophagectomy and hepatic resection for metastatic oesophageal cancer: report of a case |
| Q37797762 | The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases |
| Q38481038 | The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors |
Search more.